About Rodeo Therapeutics
Rodeo Therapeutics is a Healthcare company based in Seattle (United States) founded in 2017 by Stanton Gerson and Sanford Markowitz, and was acquired by Amgen in March 2021. Prostaglandin-degrading enzyme inhibitors are developed for inflammatory bowel disease treatment. Rodeo Therapeutics has raised $14.85 million across 2 funding rounds from investors including Amgen, AbbVie and Lilly. Its focus areas include Life Sciences, Gastroenterology, Drugs and Bowel Disorders. Its competitors include Aclaris Therapeutics, Protagonist Therapeutics and Prometheus Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Rodeo Therapeutics, a preclinical-stage biotech company, is focused on first in class small molecule modulators of prostaglandin biology for enhancing tissue repair and regeneration. The company is developing 15-PGDH (prostaglandin-degrading enzyme) inhibitors for the treatment of inflammatory bowel disease and promoting blood cell reconstitution following the bone marrow transplant (preclinical). Preclinical studies published in Science have shown that increasing PGE2 through inhibition of a prostaglandin-degrading enzyme (15-PGDH) accelerates hematopoietic stem cell reconstitution following bone marrow transplant, protects against colitis and promotes liver regeneration in a variety of animal models.
- Headquarters Seattle, United States
- Founders Stanton Gerson, Sanford Markowitz
- Stage Acquired
- SectorsHealthcare
- Website rodeotherapeutics.com
- Acquired by Amgen (Mar 2021)
Funding Insights of Rodeo Therapeutics
Rodeo Therapeutics has successfully raised a total of $14.85M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $8.95 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.85M
- Total Rounds 2
- Last Round Series A — $8.95M
- First Round $5.9M
(Aug 2017)
- Investors Count 9
All 2 funding rounds of Rodeo Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
10 investors in total: 10 institutional.
Investors in Rodeo Therapeutics
Rodeo Therapeutics has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Amgen, AbbVie and Lilly.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early stage investments focused VC firm | acks.com | |||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Venture capital services are offered for early-stage biotech companies. | acceleratorlsp.com | Seattle, United States | ||
Early-stage investments are made in Washington-based startups by WRF Capital. | wrfcapital.com | Seattle, United States | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | abbvie.com | Chicago, United States | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States | |
| jnjinnovation.com | ||||
Provider of CRO and CDMO services | 2000 | wuxiapptec.com | Shanghai, China | |
A healthcare venture capital fund focused on early-stage investments. | watsonfund.com | Seattle, United States | ||
Developer of pharmaceutical products for treating multiple diseases | 1980 | amgen.com | Thousand Oaks, United States |
Investor details for Rodeo Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Rodeo Therapeutics
1110 people are tracked at Rodeo Therapeutics (433 in leadership, 47 in board & advisors, 630 in team).
| Name | Role | Group |
|---|---|---|
Stanton Gerson | Co-Founder | Leadership |
Sanford Markowitz | Co-Founder | Leadership |
Seamus Lyons | Sr. Director Manufacturing | Leadership |
Alma Holden | Associate Director Validation | Leadership |
Francisco J Aguado-Rodriguez | Director Of Quality - Data Integrity And Ops Management Review GPO | Leadership |
Vivian Tu | Senior Director, Competitive Intelligence | Leadership |
Amro Essmat | Director , Quality - Regional Quality Head TMEA - Turkey, Middle East & Africa At Amgen | Leadership |
Miriam O'Sullivan | Executive Director Plant Manager | Leadership |
Mara Wachholder | Director, Treasury | Leadership |
Thiago Pastore | Human Resources Director, Brazil | Leadership |
Chris Pacheco | Director Manufacturing | Leadership |
Aditya Tulsyan | Associate Director Data Sciences, Operations | Leadership |
Andreas Reichelt | Senior Director Contract Manufacturing | Leadership |
Laura Cooke | Program Management Executive Director | Enterprise Transformation | Leadership |
Ned Endler | Executive Director US Trade, Channel Strategy And Execution | Leadership |
Amy Belisle | Associate Director Quality | Leadership |
Susie Tappouni | Head of Corporate Affairs | Leadership |
Kim Worrell | Associate Director HR Systems & Solutions | Leadership |
Jessica Vargas | Director, HR Business Partner | Leadership |
Mark Corder | Senior Director | Leadership |
1090 more people are available in the full profile.
Complete people profiles for Rodeo Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Rodeo Therapeutics
4 dated milestones of Rodeo Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Rodeo Therapeutics is founded.
- Funding First funding round of $5.9M.
- Funding Latest funding round, Series A, of $8.9M.
- Exit Acquired by Amgen.
Competitors of Rodeo Therapeutics
Rodeo Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Aclaris Therapeutics, Protagonist Therapeutics and Prometheus Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| protagonist-inc.com | 2001 | Milpitas, United States | $67M | 112 | Oral peptide therapeutics are developed for gastrointestinal diseases. | |
| prometheusbiosciences.com | 2016 | San Diego, United States | $130M | Drugs for gastrointestinal diseases are developed using clinical biobanks. |
Detailed competitors of Rodeo Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Gastroenterology
3 companies that operate in the same segment as Rodeo Therapeutics (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rodeo Therapeutics
Complete news archive for Rodeo Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rodeo Therapeutics
Rodeo Therapeutics was founded in 2017.
Rodeo Therapeutics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Rodeo Therapeutics is a funded company, having raised a total of $14.85M across 2 funding rounds to date. The company's 1st funding round was a Series A of $5.9M, raised on Aug 2017.
Rodeo Therapeutics, a preclinical-stage biotech company, is focused on first in class small molecule modulators of prostaglandin biology for enhancing tissue repair and regeneration. The company is developing 15-PGDH (prostaglandin-degrading enzyme) inhibitors for the treatment of inflammatory bowel disease and promoting blood cell reconstitution following the bone marrow transplant (preclinical). Preclinical studies published in Science have shown that increasing PGE2 through inhibition of a prostaglandin-degrading enzyme (15-PGDH) accelerates hematopoietic stem cell reconstitution following bone marrow transplant, protects against colitis and promotes liver regeneration in a variety of animal models.
Rodeo Therapeutics's top competitors include Aclaris Therapeutics, Protagonist Therapeutics and Prometheus Biosciences.
Rodeo Therapeutics has 10 investors. Key investors include Amgen, AbbVie, Lilly, WuXi AppTec, and Arch Venture Partners.
Yes. Rodeo Therapeutics was acquired by Amgen in March 2021.